Back to results
US 8,940,871 B2Granted
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
AssigneeThe Regents of the University of California
InventorsAnna M. Wu, Robert E. Reiter
Life of this patent
Estimating the term…
Abstract
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
Claims10
An antibody that binds to Prostate Stem Cell Antigen (PSCA) comprising:
- a light chain CDR1 of a CDR1 in SEQ ID NO:
- 6;
- a light chain CDR2 of a CDR2 in SEQ ID NO:
- 6;
- a light chain CDR3 of a CDR3 in SEQ ID NO:
- 6;
- a heavy chain CDR1 of a CDR1 in SEQ ID NO:
- 7;
- a heavy chain CDR2 of a CDR2 in SEQ ID NO:
- 7;
- and
- a heavy chain CDR3 of a CDR3 in SEQ ID NO:
- 7.
10 more elements
Dependencies are inferred from the claim text.